Inovio Pharmaceuticals (NASDAQ:INO) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Inovio Pharmaceuticals and Pro-Dex, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals 0 0 4 0 3.00
Pro-Dex 0 0 0 0 N/A

Inovio Pharmaceuticals presently has a consensus target price of $10.75, indicating a potential upside of 104.37%. Given Inovio Pharmaceuticals’ higher possible upside, equities analysts clearly believe Inovio Pharmaceuticals is more favorable than Pro-Dex.


This table compares Inovio Pharmaceuticals and Pro-Dex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inovio Pharmaceuticals -232.58% -72.66% -52.58%
Pro-Dex 9.67% 13.55% 11.23%

Insider & Institutional Ownership

34.1% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 7.6% of Pro-Dex shares are held by institutional investors. 9.4% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 41.7% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Inovio Pharmaceuticals and Pro-Dex’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inovio Pharmaceuticals $42.22 million 11.88 -$88.20 million ($1.09) -4.83
Pro-Dex $22.47 million 2.67 $1.62 million N/A N/A

Pro-Dex has lower revenue, but higher earnings than Inovio Pharmaceuticals.

Volatility and Risk

Inovio Pharmaceuticals has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.


Inovio Pharmaceuticals beats Pro-Dex on 6 of the 11 factors compared between the two stocks.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

About Pro-Dex

Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with's FREE daily email newsletter.